Latest news with #GaryPhillips
Yahoo
05-07-2025
- Sport
- Yahoo
The New York Yankees Record Against the AL East is WHAT?!
The New York Yankees Record Against the AL East is WHAT?! originally appeared on Athlon Sports. Much has been made of the New York Yankees' recent struggles. Every team has a tough stretch or some individual players that make a bad play to cost them a couple games. This Yankees stat, however, made me look at this team completely differently. Advertisement Gary Phillips of the New York Daily News noted in a recent piece that the Yankees are only 10-15 against their own division on the whole season. The Baltimore Orioles have been dead last practically since Opening Day and not competitive. Boston has had a losing record all year and shipped their best player out of town, Toronto has only played better ball over the last few weeks and Tampa doesn't even play in their own stadium. New York Yankees manager Aaron Boone (17)© David Butler II-Imagn Images That is a division that the powerhouse, reigning AL champs, $288 million team should be stepping on the throat of. And they are 10-15, even with Aaron Judge having another all-time great hitting season. Advertisement Tonight will be the finale of the Blue Jays series, then another matchup with them starting July 21st will be the next time the Yankees can make any type of improvements on their record within the division. How can they make any real changes that would impact this season? These are the teams they have to beat the most if they want to be a top seed in the postseason, or to even make it, and they have not been able to do it with their current approach. Making a trade ahead of the deadline is the simplest change, but is bringing in an extra arm or two going to fix the daily "WTF" plays? Will the other teams in the division spend so much time studying the new acquisitions, the current Yankees can perform better? I do not see it playing out like that. If a strategic or an overall attitude change happens, we won't see it right away, but the results on the field against these teams would be loud and obvious. Advertisement Quick announcement from us at Inside the Pinstripes: we are on social media! Our X and Facebook accounts will be linked going forward, but this gives YOU a chance to have your input on what you're reading here. Who's popping that we aren't seeing? What story is most important to you that we should dive into? What fired you up in this piece so much that you just HAVE to tell us how you're feeling? Reach out, have fun, and tag along for the journey! Related: Gleyber Torres Has Had a Wild Ride to Get to His 3rd All-Star Appearance This story was originally reported by Athlon Sports on Jul 3, 2025, where it first appeared.
News.com.au
23-06-2025
- Business
- News.com.au
Health Check: It's ‘nothing personal' as major US biotech fund calls time on Syntara
San Francisco's BVF Partners has exited all its ASX investments because they are too small for the fund's mandate Alcidion shares soar 15% on earnings upgrade Optiscan enters 'win-win' supplier collab Syntara (ASX:SNT) CEO Gary Phillips says the exit of a long-term US backer should not be seen as a judgment on the company's late-stage myelofibrosis drug program. In a block trade the San Francisco BVF Partners has disposed of its $5 million, 6%, Syntara stake. The shares were taken up by some of Syntara's existing institutional holders. BVF's exit last week sent Syntara shares down by 25%, despite the company's previous Friday's positive update on its phase II myelofibrosis trial update. Phillips says the trial news created a 'liquidity event' which BVF availed of. But it was not a case of BVF (as in Biotech Value Fund) spurning Syntara's drug program. Rather, the fund grew to the extent where it can't justify a minimum investment below US$30-50 million. 'They always liked our science,' Phillips says. 'They have visited our labs and were always encouraged, but they just got bigger and bigger.' With US$9 billion of assets, BVF has called time on all its ASX investments. In May BVF divested its $3 million in Actinogen Medical (ASX:ACW), also via a block trade. The fund had also invested in Opthea (ASX:OPT), but got off before the eye drug developer's' trials went pear shaped. BVF also invested in immune-oncology drug developer Viralytics, famously taken over by Merck for an eyebrow-raising $500 million in 2018. Syntara's blood cancer program looks the goods Syntara's 'liquidly event' stemmed from further data from its phase II myelofibrosis trial, evaluating its drug candidate SNT-5505 in combo with the standard-of-care drug ruxolitinib. The patients had been treated with ruxolitinib, so had symptoms such as enlarged spleen size and blood counts 'indicative of high disease burden'. The results showed eight of 11 evaluable patients (73%) achieved a reduction of more than 50% at 24 weeks, as measured by a standard gauge called TSS50. Four out of nine patients (44%) had a spleen volume reduction of 25% at week 24 or beyond. The ongoing trial enrolled 16 patients with intermediate or high-risk myelofibrosis, for 52 weeks of treatment. However, five dropped out by the 24-week mark. This is a 'withdrawal rate consistent with that seen in other myelofibrosis studies of patients with similar disease severity." Eight patients reaching 38 weeks showed and average 56% reduction in symptoms, while five reaching 52 weeks exhibited a 63% decline. Syntara intends to chat with the FDA in the September quarter about the design of a pivotal phase 2c/3 study. Too much of a good thing for Immutep? With four trial updates on separate programs in less than two months, immunology drug play Immutep (ASX:IMM) must also feel underappreciated. Immutep stock has fallen around 10% in this period and trades at close to five-year lows, despite the upbeat clinical vibes. Too much activity from the multi-tentacled Immutep confusing investors, perhaps? Today, Immutep said a phase I autoimmune study showed 'significant T-cell suppression', thus highlighting potential efficacy of its candidate IMP-761. Initial data from placebo-controlled, double-blinded effort also showed good safety at the highest dosing level to date. By stimulating the LAG-3 (lymphocyte-activation gene-3) agonist antibody, IMP-761 promises to treat conditions including rheumatoid arthritis, Type 1 diabetes and multiple sclerosis. Since May 5 Immutep also has updated investors on its head and neck cancer, lung cancer and soft tissue sarcoma trials. Miya My! Alcidion has upgraded earnings Hospital patient management software supplier Alcidion (ASX:ALC) has upped its full-year earnings outlook, with strong take-up of its flagship Miya prompting clients to adopt its broader wares. 'Over the past few months this has resulted in several customers of varying size seeking extensions or module upgrades," CEO Kate Quirke says. "This has contributed to our improved financial position." Having guided to earnings before interest, tax depreciation and amortisation of $3 million, the company now expects the number to exceed $4.5 million (for the year to June 30 2025). The company earlier guided to revenue of at least $40 million. Alcidion provides to more than 400 hospitals and 87 healthcare organisations in the UK, here and New Zealand. In the UK, the most capacious market, the beloved National Health Service (NHS) is being merged with Department of Health and Social Care. This poses both threat to – and opportunities for – Alcidion, given it sells to NHS organisations. In April, Quirke said the push for more NHS productivity with fewer staff was likely to mean greater demand for Alcidion's digital platforms. 'I see the opportunity increasing,' she said. 'But we are waiting to see what the ten-year plan indicates in terms of where the priority areas are.' PYC gets FDA OK PYC Therapeutics (ASX:PYC) has provided evidence that the FDA continues to function, with the agency approving the company's proposed trial design at a preliminary (Type B) meeting. The company currently is undergoing a phase 1-2 trial of its drug candidate VP-001, to treat the blinding eye disease retinitis pigmentosa type 11 (RP11). With positive data to date, PYC wants to progress to a phase2/3 study pitched at FDA approval. The FDA says PYC can use similar endpoints and says trial design features (such as use of a sham arm and inclusion exclusion criteria) are OK as well. The company will use this guidance to finalise its proposed registrational study design. Tryptamine study aims to put binge eating disorder to BED Meanwhile, Tryptamine Therapeutics (ASX:TYP) has won ethics approval for the world's first trial, to test intravenously infused psilocin for binge eating disorder (BED). BED is the most common eating disorder in the US and second most common here. BED results in multiple other conditions including depression, anxiety, PTSD (post-traumatic stress disorder) and compulsive behaviours. A collaboration with Swinburne University, the local trial will enrol 12 patients and administer them with with Tryptamine's drug candite TRP-8803. They will be given two doses 14 days apart and also undergo psychotherapy. The trial has started recruiting, with first dosing expected in the September quarter. Investors can expect top-line results before the year is out. The good OIL on a 'win-win' collab Optiscan (ASX:OIL) has entered a five-year collaboration agreement with the US based Long Grove Pharmaceuticals, which provides a contrast agent for Optiscan's fluorescence-based endomicroscopic imaging systems. The idea of the collab is to use Long Grove's fluorescein drug, AK-FLUOR, with Optiscan's imaging technology in clinical studies. This potentially will identify new applications for the drug and expedite regulatory submissions. On the Optiscan side of things, the data should support the company' efforts to win FDA approval for its Invue device. Invue enables surgeons to gain real-time pathology insights and make on-the-spot decisions. Optiscan CEO Dr Camile Farah dubs the agreement a 'clear-cut win-win for both companies' development strategies'.
Yahoo
18-06-2025
- Sport
- Yahoo
Boston Celtics jersey history No. 21 - Gary Philips (1961-62)
The Boston Celtics have had players suiting up in a total of 68 different jersey numbers (and have three others not part of any numerical series) since their founding at the dawn of the Basketball Association of America (BAA -- the league that would become today's NBA), worn by well over 500 players in the course of Celtics history. To commemorate the players who wore those numbers, Celtics Wire is covering the entire history of jersey numbers and the players who sported them since the founding of the team. Advertisement With 25 of those jerseys now retired to honor some of the greatest Celtics to wear those jerseys, there is a lot of history to cover. BOSTON - 1962: The World Champions of basketball Boston Celtics pose for a team portrait seated (L-R): K. C. Jones Gary Phillips, President Walter A. Brown, Head Coach Red Auerbach, Treasurer Lou Pieri, Captain Bob cousy, Sam Jones. Standing Frank Ramsey, Tom Sanders, tom Heinsohn, Bill russell Gene Guarillia, Jim Loscutoff, Carl Brown, Trainer Buddy LeRoux in Boston, Massachusetts in 1962. NOTE TO USER: User expressly acknowledges and agrees that, by downloading and or using this photograph, User is consenting to the terms and conditions of the Getty Images License Agreement. Mandatory copyright notice: Copyright NBAE 2002 (Photo by NBAP/ NBAE/ Getty Images) And for today's article, we will continue with the sixth of nine people to wear the No. 21, Boston guard alum Gary Phillips. After ending his college career at Houston, Phillips was picked up with the ninth overall selection of the 1961 NBA draft by the Celtics. The Quincy, Illinois native would play the first season of his pro career with Boston before he was dealt to the (then) San Francisco (now, Golden State) Warriors in 1962. During his time suiting up for the Celtics, Phillips wore only jersey No. 21 and put up 4.0 points, 1.6 rebounds, and 1.0 assists per game. All stats and data courtesy of Basketball Reference. This article originally appeared on Celtics Wire: Celtics jersey history No. 21 - Gary Philips (1961-62)
Yahoo
21-05-2025
- Sport
- Yahoo
NYY News: Rotation rounding into form
New York Daily News | Gary Phillips: Three-fifths of the intended Opening Day starting rotation is on the IL, with Gerrit Cole out for the year while Luis Gil and Marcus Stroman try to rehab and rejoin the club. Despite those blows, the Yankee rotation is rounding into form well, not just because of Max Fried. The starting staff was the worst in baseball in the season's first two weeks, but since then boast the second-best ERA in the game. The only squad better is the Texas Rangers, so this week should be a fun series. | Jacob Foster: A cadre of writers cast their votes for Rookie of the Year favorites now that we're about a quarter of the way through the season. Jasson Domínguez, still just 22, gets himself some scattered votes but no first-place slots, as the outfielder has earned himself everyday playing time, but doesn't quite measure up to the top two first-year players in the American League. The Martian still has three quarters of the season to catch up. Advertisement FanGraphs | Dan Szymborski: With the quarter pole in our review mirror, Dan takes us through the players whose ZiPS projections have most changed, for better and worse. On the 'best' front, ZiPS seems to be something of a believer in Trent Grisham's terrific start, and is also high on prospect George Lombard Jr. The Yankees have a rolling offense for now, and sure enough, don't have any names on the downgrade list. More from
